Impact of Polycystic Ovary Syndrome on Liver, Cardiac, Muscular, and Pancreatic Health

Overview

Polycystic ovary syndrome (PCOS) is a systemic metabolic disorder affecting multiple organs beyond the ovaries, including the liver, heart, muscles, and pancreas. Obese women with PCOS show a high prevalence of metabolic dysfunction–associated steatotic liver disease (51.61%) and face a 2–4 fold increased risk of cardiovascular disease and type 2 diabetes.

Background

PCOS affects 11–13% of women of reproductive age and is characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology. Its pathogenesis involves insulin resistance, inflammation, and oxidative stress, which extend systemic metabolic disturbances beyond reproductive dysfunction. The syndrome's multi-organ impact includes hepatic steatosis, cardiovascular injury, pancreatic β-cell exhaustion, and muscular sarcopenia, necessitating a comprehensive, multidisciplinary management approach.

Data Highlights

Key Findings

• PCOS is a systemic metabolic disorder involving insulin resistance, hyperandrogenism, inflammation, and oxidative stress affecting multiple organs.
• Obese women with PCOS have a 51.61% prevalence of metabolic dysfunction–associated steatotic liver disease (MASLD).
• PCOS increases cardiovascular disease risk by 2–4 fold through mechanisms including chronic inflammation and sympathetic overactivation.
• There is a 1.9-fold higher risk of pancreatic cancer and increased incidence of type 2 diabetes and β-cell dysfunction in PCOS patients.
• PCOS-related insulin resistance and inflammation contribute to muscular complications such as sarcopenia and decreased muscle strength.
• The hyperandrogenic phenotype of PCOS is associated with more severe hepatic steatosis and fibrosis, highlighting disease heterogeneity.

Clinical Implications

Clinicians should recognize PCOS as a systemic metabolic disease requiring integrated multidisciplinary care beyond reproductive symptom management. Screening for hepatic steatosis, cardiovascular risk factors, pancreatic dysfunction, and muscular health is essential, especially in obese patients. Therapeutic strategies targeting shared pathophysiological pathways such as insulin resistance and inflammation may improve multi-organ outcomes.

Conclusion

PCOS extends far beyond ovarian dysfunction, manifesting as a systemic metabolic disorder with significant hepatic, cardiovascular, pancreatic, and muscular complications. Addressing these interconnected manifestations through comprehensive, multidisciplinary management is critical to improving patient outcomes.

References

1. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group 2003 -- Revised 2003 consensus on diagnostic criteria
2. Various Authors 2024 -- Impact of Polycystic Ovary Syndrome on Liver, Cardiac, Muscular, and Pancreatic Health Issues